• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anthem, Novo Nordisk team up for real-world diabetes drug study

October 17, 2018 By Sarah Faulkner

Novo Nordisk, AnthemAnthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes.

The real-world trial is designed to compare the long-term effectiveness of the drug, also known as Ozempic, against 40 other medications among 2,250 adults with Type 2 diabetes.

“Because the Sepra trial seeks to find out what happens with people using anti-diabetic therapies after FDA approval, it may be of greater interest to more people and doctors than a standard randomized clinical trial, which requires intense monitoring and coaching of consumers to take medications,” study clinical advisor Dr. John Buse said in prepared remarks. “This trial will be relying on how doctors work with their patients in the real world with little outside guidance.”

Researchers plan to follow the trial participants for two years, measuring which participants meet their HbA1c goals. The trial will also evaluate how often participants land in the hospital due to diabetes-related conditions. Researchers also plan to examine factors like participants’ body weight change, quality of life, rates of hypoglycemia and medication adherence.

“We are proud to be a leader in the field of pragmatic study research,” lead researcher Vince Willey said. “We believe this type of collaboration and acceleration of research demonstrated in Sepra will help in identifying the therapies with the best outcomes for a large and diverse population.”

“We strongly believe in the clinical value of this medication, and are excited to learn more about its real-world use in adults with Type 2 diabetes,” Todd Hobbs, Novo Nordisk’s CMO, added. “We invest in studies like Sepra because payers and physicians want to know how to achieve high quality care that’s cost effective.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Anthem, Novo Nordisk

IN CASE YOU MISSED IT

  • Rapid Dose closes first tranche of $5M financing
  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS